Molecular Disease Characterization Initiative (MDCI)

Clinical trial NCT04772053 · TERMINATED

Trial details

NCT number: NCT04772053
Sponsor: GlaxoSmithKline
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer, Non-Small Cell Neoplasms

Start date: 2021-05-25
Primary completion: 2022-11-15
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.